Related Experiment Video

Updated: Jul 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer

Vincent A Miller1

  • 1Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. millerv@mskcc.org

Seminars in Oncology Nursing
|January 29, 2008
PubMed
Abstract

Insights

Molecular targets and clinical variables are key for predicting outcomes in non-small cell lung cancer (NSCLC) patients receiving EGFR-TKI therapy. This personalized approach promises improved results over traditional chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Medicine

Background:

  • Non-small cell lung cancer (NSCLC) treatment is evolving.
  • Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) offer targeted therapy options.
  • Identifying predictive and prognostic markers is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To review key molecular targets for NSCLC.
  • To discuss clinical variables as predictive and prognostic markers.
  • To inform treatment decisions for NSCLC patients undergoing EGFR-TKI therapy.

Main Methods:

  • Literature review of research and journal articles.
  • Synthesis of information on molecular targets and clinical variables.
  • Analysis of their role in predicting and prognosticating outcomes.

Main Results:

  • Selected molecular targets show promise in guiding NSCLC treatment.
  • Specific clinical variables can predict patient response and prognosis.
  • EGFR-TKIs represent a significant advancement in targeted NSCLC therapy.

Conclusions:

  • Future NSCLC treatment will increasingly depend on molecular targets.
  • Personalized medicine approaches will improve patient outcomes.
  • Understanding these markers enhances nursing care for NSCLC patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...